Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.66 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.36 |
| ▸ | COMT | P21964 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5100840 | 0.80 | GRM5 (1.00) | GRM5 | |
| SCHEMBL5077800 | 0.78 | GRM5 (0.53) | GRM5 | |
| SCHEMBL5081724 | 0.77 | GRM5 (0.56) | GRM5GRIA1GRIA3PDE4D | |
| Hydrochloric Acid SCHEMBL5082253 | 0.77 | GRM5 (0.52) | GRM5 | |
| SCHEMBL5107073 | 0.74 | GRM5 (0.72) | GRM5 | |
| SCHEMBL5108108 | 0.74 | GRM5 (0.72) | GRM5 | |
| SCHEMBL5104221 | 0.74 | GRM5 (0.72) | GRM5 | |
| SCHEMBL5107578 | 0.74 | GRM5 (0.72) | GRM5 | |
| SCHEMBL28371479 | 0.73 | ALDH1A1 (0.46) | GRM5GRIA1GRIA3PDE4DPLAUR | |
| SCHEMBL13261822 | 0.72 | METAP2 (0.50) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393959-B2 | Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5 | MERCK & CO. INC. (US) | 2008-07-01 | — | — | US | claimed |
| EP-1613265-A4 | DI-ARYL SUBSTITUTED PYRROLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2007-02-14 | — | — | EP | claimed |
| US-20060193926-A1 | Di-arylsubstituted pyrrole modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2006-08-31 | — | — | US | claimed |
| EP-1613265-A2 | DI-ARYL SUBSTITUTED PYRROLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2006-01-11 | — | — | EP | claimed |
| WO-2004089308-A2 | DI-ARYL SUBSTITUTED PYRROLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2004-10-21 | — | — | WO | claimed |
| US-7393959-B2 | Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5 | MERCK & CO. INC. (US) | 2008-07-01 | — | — | US | disclosed |
| EP-1613265-A4 | DI-ARYL SUBSTITUTED PYRROLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20060193926-A1 | Di-arylsubstituted pyrrole modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2006-08-31 | — | — | US | disclosed |
| EP-1613265-A2 | DI-ARYL SUBSTITUTED PYRROLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004089308-A2 | DI-ARYL SUBSTITUTED PYRROLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060193926-A1 | Di-arylsubstituted pyrrole modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRIN2B | GRM5 1/4885GRIA1 12/4885GRIA3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.